3 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
Follow Carcinosarcoma: new trials by email Literature Review of Carcinosarcoma trials Research Report on Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma Camrelizumab Combined With Apatinib - PD-1 Immunotherapy, VEGFR-TKI | Phase 2 | Unknown | Fudan University | 45 | 2021-11-21 | 2022-03-04 |
| Nivolumab for Recurrent/Metastatic Carcinosarcoma nivolumab - Recurrent/Metastatic Carcinosarcoma | Phase 2 | Unknown | Yonsei University | 28 | 2019-11-13 | 2022-02-04 |
| Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Paclitaxel, Cediranib, Olaparib - Carcinosarcoma, Endometrial Neoplasms | Phase 2 | Unknown | University of Manchester | 124 | 2018-05-17 | 2022-03-02 |
Carcinoma (1) · Endometrial Neoplasms (1) · Neoplasms (1)
Neoplasms by Histologic Type (3) · Neoplasms, Complex and Mixed (3) · Neoplasms, Connective and Soft Tissue (3) · Sarcoma (3) · Neoplasms (2) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1)
Nivolumab (1) · Paclitaxel (1) · apatinib (1) · cediranib (1) · olaparib (1)
Fudan University (1) · University of Manchester (1) · Yonsei University (1)
China (1) · South Korea (1) · United Kingdom (1)
Gordon Jayson (1)
2016 (1)